- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00642980
Prevention of Very Preterm Delivery by Testing for and Treatment of Bacterial Vaginosis (PREMEVA)
Randomized Multicenter Trial for the Prevention of Preterm Delivery by Testing for and Treatment of Bacterial Vaginosis in the First Trimester of Pregnancy
Background. Anomalies of the vaginal flora (bacterial vaginosis, BV) are associated with an increased risk of late abortions and preterm birth. Studies of antibiotic treatment of BV to reduce the risk of prematurity have not found a statistically significant diminution of risk (<= 32 wks: OR=0.49 [0.05-5.1], < 37 wks: OR=0.83 [0.59-1.17]).A partial explanation of these findings is that some of these treatment were administered vaginally, most often during the second or third trimester
Aim: To reduce the frequency of late abortions and very preterm birth by prescribing clindamycin vs placebo to patients diagnosed with BV before 13 weeks.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Patients diagnosed with BV before 13 weeks will be divided into two groups. They will be defined as at low risk when they have no history of spontaneous preterm delivery or late abortion. Women with such histories will be defined as at high risk.
Low risk patients will be asked to participate in a trial with 3 equal parallel groups, comparing two regimes of clindamycin (one or three 4-day treatments of clindamycin 300 mgx2/d) and placebo.
High-risk patients will be asked to participate in a trial with 2 parallel groups to assess the usefulness of repeating antibiotic treatment monthly by comparing the administration of one 4-day treatment of clindamycin (300 mgx2/d) to three 4-day treatments, one month apart.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Lille, France, 59 000
- Hopital Jeanne de Flandre
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Nugent score >= 7
- pregnant women < 15 weeks (strictly)
- signed informed consent
- >=18 old
- speaking and understanding French language
Exclusion Criteria:
- metrorrhagias during 7 days before
- birth anticipated in an other area
- clindamycin allergy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Clindamycin Cure 1
Arm 1
|
300 mg capsules (per os) Intervention= 2 capsules/d during 4 days: three times a month apart
Other Names:
300 mg capsules (per os) Intervention= 2 capsules/d during 4 days: one time and then, after one month placebo capsules 2 capsules/d during 4 days: two times a month apart
Other Names:
|
Active Comparator: Clindamycin Cure 2
Arm 2
|
300 mg capsules (per os) Intervention= 2 capsules/d during 4 days: three times a month apart
Other Names:
300 mg capsules (per os) Intervention= 2 capsules/d during 4 days: one time and then, after one month placebo capsules 2 capsules/d during 4 days: two times a month apart
Other Names:
|
Placebo Comparator: Placebo
Arm placebo
|
Double blinded capsules(per os) Intervention= 2 capsules/d during 4 days: three times a month apart
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Premature delivery (16 to 32 weeks of gestation)
Time Frame: At delivery
|
At delivery
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Preterm labor, PPROM, Spontaneous preterm labor, PROM, Abruptio placentae, Chorioamnionitis, Fever > 38°C during labor, Post partum fever (> 38°), Post-partum wound infections, Perinatal death, NICU transfer, Bacterial neonatal colonisation.
Time Frame: At delivery
|
At delivery
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Damien SUBTIL, MD PhD, University Hospital, Lille (France)
- Study Chair: Gilles Brabant, MD, Groupe Hospitalier de l' Institut Catholique, Lille
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Infections
- Bacterial Infections
- Bacterial Infections and Mycoses
- Pregnancy Complications
- Obstetric Labor Complications
- Obstetric Labor, Premature
- Vaginitis
- Premature Birth
- Vaginal Diseases
- Vaginosis, Bacterial
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Anti-Bacterial Agents
- Protein Synthesis Inhibitors
- Clindamycin
- Clindamycin palmitate
- Clindamycin phosphate
Other Study ID Numbers
- 060216
- PHRC 2004/1918 (Other Identifier: DHOS)
- PHRC 2008/1929 (Other Identifier: DHOS)
- 2004/0428 (Other Identifier: sponsor)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pregnancy
-
Far Eastern Memorial HospitalCompletedCornual PregnancyTaiwan
-
Peking Union Medical College HospitalPeking Union Medical CollegeUnknownPregnancy | Pregnancy Related | Infant | Pregnancy Disease | Risk FactorChina
-
Ufuk UniversityNot yet recruitingPregnancy Complications | Pregnancy Loss | Pregnancy Preterm
-
Hadassah Medical OrganizationCompleted
-
Centre Hospitalier Universitaire de Saint EtienneCompletedProlonged PregnancyFrance
-
University Hospital, ToursCompleted
-
Technische Universität DresdenWithdrawnPregnancy Trimester, Second | Pregnancy Trimester, First | Pregnancy Trimester, ThirdGermany
-
Turku University HospitalUniversity of TurkuCompleted
-
Hopital Antoine BeclereUnknown
-
Universitair Ziekenhuis BrusselMerck Serono International SAUnknownPregnancy | Pregnancy LossBelgium
Clinical Trials on Clindamycin
-
Phillip Brian SmithEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedSafety and Pharmacokinetics of Clindamycin in Pediatric Subjects With BMI ≥ 85th Percentile (CLIN01)Obesity | Bacterial InfectionsUnited States
-
Taro Pharmaceuticals USACompletedAcne VulgarisUnited States
-
Alexandria UniversityNot yet recruitingInfection, BacterialEgypt
-
Akorn, Inc.CompletedAcne VulgarisUnited States, Belize
-
St. Luke's Hospital, PennsylvaniaCompletedPneumothorax | HemopneumothoraxUnited States
-
Lumara Health, Inc.CompletedVaginitis | VulvovaginitisUnited States, Russian Federation, Puerto Rico, India
-
United States Naval Medical Center, PortsmouthUnknown
-
Shahid Beheshti University of Medical SciencesCompletedEndophthalmitis | Prophylaxy of Post Traumatic Endophthalmitis | Bacterial EndophthalmitisIran, Islamic Republic of
-
Albert Schweitzer HospitalCompleted
-
Stiefel, a GSK CompanyGlaxoSmithKline; Quintiles, Inc.; Rho, Inc.CompletedAcne VulgarisUnited States, Canada, Belize